Novo Nordisk GLP-1 fails to slow Alzheimer’s in trials

Ella Jeffries / beckershospitalreview - Novo Nordisk’s GLP-1 drug semaglutide did not demonstrate a statistically significant effect in slowing progression of Alzheimer’s disease in two late-stage clinical trials. According to a Nov. 24 news release from the company, two double-blinded, placebo…

AI Summary: Novo Nordisk’s much‑talked‑about GLP‑1 drug, famed for its weight‐loss benefits, has hit an unexpected wall in Alzheimer’s trials. In two separate reports – one on the standard injectable and another on a pill form – semaglutide showed no statistically significant impact on slowing brain decline. Who knew obesity meds couldn’t multitask?

#obesity #healthcare #pharmaceuticals #novonordisk #weightloss #publichealth #biotech #drugdevelopment

CMS unveils negotiated prices for Ozempic, Wegovy and other drugs from second round of IRA talks

6 months / endpoints / Nicole DeFeudis

Postpartum Prescription of GLP-1 Drugs Has Increased Sharply, Study Finds

6 months / nytimes / Roni Caryn Rabin

Novo Nordisk GLP-1 fails to slow Alzheimer’s in trials

6 months / beckershospitalreview / Ella Jeffries

Pill form of semaglutide fails to slow Alzheimer's in large trial

6 months / medicalxpress

Ozempic Drug Fails to Quell Alzheimer’s in Novo Nordisk Trials

6 months / nytimes / Gina Kolata

StackHealth RSS

You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Pfizer, Olfaction, Healthcare, Research Funding and look for the RSS link.

StackHealth Time Machine

More StackHealth